Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort - Report - MDSpire
Advertisement
Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort
Clinical Report: Real-World Safety and Efficacy of Ofatumumab in MS
Overview
Ofatumumab demonstrated significant reductions in relapse rates and MRI activity in both treatment-naïve patients and those switching from other therapies. The study also found that prior exposure to high-efficacy therapies was the only independent predictor of infection risk under ofatumumab.
Background
Multiple sclerosis (MS) is a leading cause of long-term neurological disability among young adults, necessitating effective treatment strategies. Anti-CD20 monoclonal antibodies like ofatumumab have shown promise in managing relapsing MS by targeting B cells, which play a crucial role in disease pathogenesis. Understanding the real-world efficacy and safety of ofatumumab is essential for optimizing treatment approaches, especially for patients with varying treatment histories.
Data Highlights
No numerical data provided in the source material.
Key Findings
Ofatumumab achieved substantial reductions in relapse rates and MRI activity.
High rates of NEDA-3 were observed across both treatment-naïve patients and switchers.
Disability outcomes remained stable over follow-up with no significant differences across treatment subgroups.
Prior exposure to high-efficacy therapies was the only independent predictor of infection risk.
Multivariable sensitivity analyses confirmed the robustness of the findings regarding disability outcomes.
Clinical Implications
Clinicians should consider the history of prior treatments when prescribing ofatumumab, as it may influence infection risk. The stability of disability outcomes across treatment subgroups suggests that ofatumumab can be a viable option for diverse patient populations in real-world settings.
Conclusion
This study reinforces the effectiveness and safety of ofatumumab in managing relapsing MS, highlighting the importance of real-world evidence in guiding treatment decisions.
